查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2065185

互聯藥物傳輸設備市場預測至2034年－按產品類型、技術、給藥途徑、治療領域、通路、最終用戶和地區分類的全球分析

Connected Drug Delivery Devices Market Forecasts to 2034 - Global Analysis By Product Type, Technology, Route of Administration, Therapeutic Area, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球互聯藥物輸送設備市場預計將在 2026 年達到 42 億美元，到 2034 年達到 128 億美元，預測期內複合年成長率為 14.9%。

互聯藥物輸送裝置是具備數位化功能的智慧治療系統，它將傳統的藥物傳輸機制與整合感測器、無線連接和數據分析功能相結合。這些裝置能夠即時向醫療專業人員、看護者和數位健康平台傳輸劑量、依從性和生理數據。透過實現遠端監測和個人化治療管理，它們有助於提高患者的用藥依從性，改善臨床療效，並有效管理各種急性疾病。

慢性病盛行率的上升推動了對以藥物依從性為中心的管理系統的需求。

隨著糖尿病、氣喘和自體免疫疾病等慢性病在全球日益加重，提高患者用藥依從性的需求也日益迫切。互聯藥物輸送設備能夠將即時用藥數據傳輸給臨床醫生和看護者，從而有效應對這項挑戰，以實現及時介入。隨著醫療保健系統向以金額為準醫療模式轉型，保險公司和醫療服務提供者正加強獎勵能夠減少因用藥依從性差而導致的住院治療的技術。以病人為中心的醫療模式與數位化治療方法的融合，正在加速這些平台在全球醫院和居家照護機構的應用。

嚴格的監管要求和漫長的核准流程

將連網藥物輸送設備推向市場需要同時遵守藥品和醫療設備法規，包括取得FDA 510(k)許可、PMA批准以及歐盟MDR標準。這種雙重監管流程顯著延長了研發週期並增加了合規成本。此外，整合醫療器材軟體（SaMD）組件還會引入網路安全審查要求，進一步加劇核准流程的複雜性。中小型製造商和新興市場企業在滿足這些標準方面面臨不成比例的挑戰，導致其市場准入受限，創新產品在全球市場的推廣速度也較為緩慢。

拓展數位療法和遠端患者監護的生態系統

數位健康平台和遠端患者監護解決方案的快速普及，為互聯藥物輸送設備創造了巨大的整合機會。製藥公司正與數位健康公司合作，建立「閉合迴路治療」生態系統，利用設備數據調整劑量並支持臨床決策。北美和歐洲的保險報銷體係正在擴大連網型設備項目的覆蓋範圍，這為保險公司展現了商業價值。 5G基礎設施和物聯網醫療網路的持續擴展，進一步提升了即時數據傳輸能力，推動了腫瘤學、神經病學和罕見疾病管理等領域新型治療應用的發展。

互聯平台中的資料隱私漏洞與網路安全風險

連網藥物輸送設備是網路安全威脅的主要目標，因為它們會持續產生和傳輸敏感的患者健康資訊。未授權存取給藥記錄、用藥依從性或生物識別資料可能會侵犯病患隱私，並使醫療機構面臨 HIPAA 和 GDPR 等法規的處罰。設備生態系統中使用的無線通訊協定各不相同，這會導致互通性差距，進而引發安全漏洞。隨著這些設備日益融入臨床工作流程，確保端到端資料加密並維護健全的網路安全管治仍然是製造商和醫療服務提供者面臨的關鍵且持續的挑戰。

新型冠狀病毒（COVID-19）的影響

新冠疫情凸顯了遠端醫療管理的迫切性，顯著加速了對互聯藥物輸送設備的需求。封鎖措施和醫院容量限制迫使病患和醫療服務提供者轉向居家照護模式，使這些設備成為在臨床環境之外管理慢性疾病的重要工具。疫情推動的監管彈性也加速了數位健康產品的核准，並更快地將新的連網解決方案推向市場。隨著全球醫療體係以韌性和數位化為核心優先事項進行重組，疫情期間累積的勢頭將繼續推動互聯藥物輸送生態系統的持續投資和應用。

在預測期內，整合式連網型設備細分市場預計將佔據最大的市場佔有率。

由於其將藥物輸送機制與嵌入式和感測功能整合於單一平台的綜合設計，整合連網型設備領域預計將在預測期內佔據最大的市場佔有率。受呼吸系統和代謝性疾病日益普遍的推動，互聯吸入器和連網注射器正迅速普及。醫療專業人員更傾向於無需額外硬體並簡化患者導入流程的整合解決方案。製藥公司正透過推出一系列將生物製藥和專科療法與其專有互聯輸送平台結合的複合產品，進一步鞏固其在該領域的領先地位。

預計在預測期內，智慧包裝和監控設備細分市場將實現最高的複合年成長率。

在預測期內，智慧包裝和監測設備領域預計將呈現最高的成長率，這主要得益於口服藥物治療領域整體經濟高效的用藥依從性監測解決方案日益成長的需求。智慧藥瓶和智慧泡殼包裝正迅速受到進行臨床試驗和管理老年人複雜多重用藥聯合治療的製藥公司的青睞。這些設備提供了一種非侵入式的用藥依從性追蹤方法，並且與現有的藥品供應鏈相容。北美和歐洲有利的保險報銷趨勢，以及藥房日益成長的數位化努力，進一步推動了智慧包裝技術的應用。

市佔率最大的地區

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其先進的醫療保健基礎設施、沉重的慢性病負擔以及強大的數位健康生態系統。美國受益於完善的互聯連線健診技術報銷體系，以及由製藥創新者和醫療技術公司組成的緊密網路，這些都推動了產品開發。患者對數位療法的認知度不斷提高，加上美國食品藥物管理局（FDA）對軟體驅動型醫療設備的支持性法規，進一步鞏固了該地區在全球互聯藥物輸送設備市場的主導地位。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的快速擴張、智慧型手機普及率的不斷提高以及人們對慢性病管理技術的日益關注。中國、印度、日本和韓國等國家正大力投資數位健康生態系統和互聯醫療設備創新。中產階級醫療費用支出的成長以及政府主導的數位轉型（DX）舉措，為市場准入創造了有利條件。該地區擁有大量存在未滿足的用藥依從性管理需求的患者，這為全球和區域互聯藥物輸送設備製造商提供了巨大的商業化機會。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地域覆蓋和策略聯盟對標領先企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球互聯藥物輸送設備市場：依產品類型分類

  • 聯網感測器
    • 用於連接式吸入器的感測器
    • 可連接式噴射感測器
    • 附加元件智慧帽和模組
  • 整合連網型設備
    • 連接式吸入器
    • 連接式注射裝置
  • 智慧包裝和監控設備
    • 智慧藥瓶
    • 智慧吸塑包裝

第6章 全球互聯藥物輸送設備市場：依技術分類

  • Bluetooth
  • 近距離場通訊（NFC）
  • Wi-Fi
  • 蜂窩/低功耗廣域網路連接
  • 基於雲端的平台
  • 其他

第7章 全球互聯藥物輸送設備市場：依給藥途徑分類

  • 注射/腸外給藥
  • 吸入式
  • 口服給藥
  • 經皮給藥

第8章 全球互聯藥物輸送設備市場：依治療領域分類

  • 糖尿病管理
  • 呼吸系統疾病
  • 自體免疫疾病
  • 心血管疾病
  • 神經病變
  • 腫瘤學
  • 內分泌疾病
  • 其他慢性疾病

第9章 全球互聯藥物輸送設備市場：按分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 直銷

第10章 全球互聯藥物輸送設備市場：依最終用戶分類

  • 醫院
  • 診所和專科醫療中心
  • 居家醫療
  • 門診部
  • 製藥和生物技術公司
  • 患者和看護者

第11章 全球互聯藥物輸送設備市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Medtronic plc
  • Becton, Dickinson and Company
  • Ypsomed AG
  • West Pharmaceutical Services, Inc.
  • Phillips-Medisize Corporation
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • AptarGroup, Inc.
  • BIOCORP
  • Adherium Limited
  • Propeller Health
  • Gerresheimer AG
  • ResMed Inc.
Product Code: SMRC36770

According to Stratistics MRC, the Global Connected Drug Delivery Devices Market is accounted for $4.2 billion in 2026 and is expected to reach $12.8 billion by 2034, growing at a CAGR of 14.9% during the forecast period. Connected Drug Delivery Devices are smart, digitally enabled therapeutic systems that combine conventional drug administration mechanisms with integrated sensors, wireless connectivity, and data analytics capabilities. These devices transmit dosage, adherence, and physiological data in real time to healthcare providers, caregivers, and digital health platforms. By enabling remote monitoring and personalized therapy management, they improve patient compliance, clinical outcomes, and disease control across a broad spectrum of chronic and acute conditions.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases driving demand for adherence-focused delivery systems

The growing global burden of chronic illnesses such as diabetes, asthma, and autoimmune disorders has intensified the need for medication adherence solutions. Connected drug delivery devices address this challenge by transmitting real-time usage data to clinicians and caregivers, enabling timely interventions. As healthcare systems shift toward value-based care models, payers and providers are increasingly incentivizing technologies that reduce hospitalizations caused by non-adherence. The convergence of patient-centric care and digital therapeutics is accelerating adoption of these platforms across hospital and home care settings globally.

Restraint:

Stringent regulatory requirements and lengthy approval timelines

Bringing connected drug delivery devices to market requires dual compliance with both pharmaceutical and medical device regulations, including FDA 510(k) clearance or PMA approval and adherence to EU MDR standards. This dual-pathway regulatory burden significantly extends development timelines and escalates compliance costs. Additionally, integrating software-as-a-medical-device (SaMD) components introduces cybersecurity review requirements that further complicate approvals. Smaller manufacturers and emerging-market companies face disproportionate challenges in meeting these standards, limiting competitive entry and slowing innovation diffusion across global markets.

Opportunity:

Expansion of digital therapeutics and remote patient monitoring ecosystems

The rapid proliferation of digital health platforms and remote patient monitoring solutions creates significant integration opportunities for connected drug delivery devices. Pharmaceutical companies are partnering with digital health firms to build closed-loop therapy ecosystems where device data informs dose adjustments and clinical decision support. Reimbursement frameworks in North America and Europe are increasingly covering connected device programs, validating the business case for payers. The ongoing expansion of 5G infrastructure and IoT healthcare networks further enhances real-time data transmission capabilities, unlocking new therapeutic applications in oncology, neurology, and rare disease management.

Threat:

Data privacy vulnerabilities and cybersecurity risks in connected platforms

Connected drug delivery devices continuously generate and transmit sensitive patient health information, making them prime targets for cybersecurity threats. Unauthorized access to dosage records, adherence patterns, or biometric data can compromise patient privacy and expose healthcare organizations to regulatory penalties under HIPAA and GDPR. The heterogeneity of wireless communication protocols used across device ecosystems creates interoperability gaps that may introduce security vulnerabilities. As these devices become increasingly embedded within clinical workflows, ensuring end-to-end data encryption and maintaining rigorous cybersecurity governance remain critical and ongoing challenges for manufacturers and healthcare providers alike.

Covid-19 Impact:

The COVID-19 pandemic substantially accelerated demand for connected drug delivery devices by highlighting the urgent need for remote therapy management. Lockdowns and hospital capacity constraints drove patients and providers toward home-based care models, positioning these devices as essential tools for chronic disease management outside clinical settings. Pandemic-driven regulatory flexibilities also expedited digital health approvals, bringing new connected solutions to market faster. As healthcare systems worldwide rebuild with resilience and digitization as core priorities, the momentum gained during the pandemic continues to fuel sustained investment and adoption in connected drug delivery ecosystems.

The integrated connected devices segment is expected to be the largest during the forecast period

The integrated connected devices segment is expected to account for the largest market share during the forecast period, owing to its comprehensive design that combines drug delivery mechanisms with embedded connectivity and sensing capabilities in a single platform. Connected inhalers and connected injectable devices are experiencing strong adoption driven by growing respiratory and metabolic disease prevalence. Healthcare providers favor integrated solutions that eliminate the need for add-on hardware and simplify patient onboarding. Pharmaceutical companies are increasingly launching combination products that pair biologics and specialty drugs with proprietary connected delivery platforms, reinforcing the dominance of this segment.

The smart packaging & monitoring devices segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the smart packaging & monitoring devices segment is predicted to witness the highest growth rate, driven by escalating demand for cost-effective adherence monitoring solutions across oral drug therapies. Smart pill bottles and smart blister packs are gaining rapid traction among pharmaceutical companies conducting clinical trials and managing complex multi-drug regimens in elderly populations. These devices offer a non-invasive adherence tracking approach compatible with existing pharmaceutical supply chains. Favorable reimbursement trends and growing pharmacy digitization initiatives in North America and Europe are further propelling adoption of smart packaging technologies.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by the region's advanced healthcare infrastructure, high chronic disease burden, and robust digital health ecosystem. The United States benefits from a well-established reimbursement environment for connected health technologies, alongside a dense network of pharmaceutical innovators and medtech companies driving product development. Strong patient awareness of digital therapeutics, combined with supportive regulatory initiatives from the FDA toward software-enabled medical devices, reinforces the region's leadership position in the global connected drug delivery devices landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by rapidly expanding healthcare infrastructure, increasing smartphone penetration, and growing awareness of chronic disease management technologies. Countries such as China, India, Japan, and South Korea are investing heavily in digital health ecosystems and connected medical device innovation. Rising middle-class healthcare spending and government-led digital transformation initiatives are creating favorable conditions for market entry. The region's large patient population with unmet adherence management needs presents substantial commercialization opportunities for global and regional connected drug delivery device manufacturers.

Key players in the market

Some of the key players in Connected Drug Delivery Devices Market include Medtronic plc, Becton Dickinson and Company, Ypsomed AG, West Pharmaceutical Services Inc., Phillips-Medisize Corporation, Insulet Corporation, Tandem Diabetes Care Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., BIOCORP, Adherium Limited, Propeller Health, Gerresheimer AG, and ResMed Inc.

Key Developments:

In March 2026, Medtronic announced the global launch of its next-generation connected insulin delivery platform integrated with continuous glucose monitoring capabilities. The system enables automated dose adjustment recommendations transmitted directly to patient smartphones and clinician dashboards, targeting improved glycemic outcomes for Type 1 and Type 2 diabetes patients in both hospital and home care settings.

In January 2026, Becton Dickinson and Company announced a strategic collaboration with a leading digital therapeutics company to co-develop a connected injectable drug delivery platform incorporating adherence tracking and real-time patient reporting features. The partnership aims to accelerate the commercialization of combination biologics-device products targeting autoimmune disease and oncology therapy segments.

Product Types Covered:

  • Connected Sensors
  • Integrated Connected Devices
  • Smart Packaging & Monitoring Devices

Technologies Covered:

  • Bluetooth
  • Near Field Communication (NFC)
  • Wi-Fi
  • Cellular / LPWAN Connectivity
  • Cloud-Based Platforms
  • Other Technologies

Routes of Administration Covered:

  • Injectable / Parenteral
  • Inhalational
  • Oral Drug Delivery
  • Transdermal Delivery

Therapeutic Areas Covered:

  • Diabetes Management
  • Respiratory Diseases
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Oncology
  • Hormonal Disorders
  • Other Chronic Diseases

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Sales

End Users Covered:

  • Hospitals
  • Clinics & Specialty Centers
  • Home Care Settings
  • Ambulatory Care Centers
  • Pharmaceutical & Biotech Companies
  • Patients & Caregivers

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Connected Drug Delivery Devices Market, By Product Type

  • 5.1 Connected Sensors
    • 5.1.1 Connected Inhaler Sensors
    • 5.1.2 Connectable Injection Sensors
    • 5.1.3 Add-on Smart Caps & Modules
  • 5.2 Integrated Connected Devices
    • 5.2.1 Connected Inhalers
    • 5.2.2 Connected Injectable Devices
  • 5.3 Smart Packaging & Monitoring Devices
    • 5.3.1 Smart Pill Bottles
    • 5.3.2 Smart Blister Packs

6 Global Connected Drug Delivery Devices Market, By Technology

  • 6.1 Bluetooth
  • 6.2 Near Field Communication (NFC)
  • 6.3 Wi-Fi
  • 6.4 Cellular / LPWAN Connectivity
  • 6.5 Cloud-Based Platforms
  • 6.6 Other Technologies

7 Global Connected Drug Delivery Devices Market, By Route of Administration

  • 7.1 Injectable / Parenteral
  • 7.2 Inhalational
  • 7.3 Oral Drug Delivery
  • 7.4 Transdermal Delivery

8 Global Connected Drug Delivery Devices Market, By Therapeutic Area

  • 8.1 Diabetes Management
  • 8.2 Respiratory Diseases
  • 8.3 Autoimmune Diseases
  • 8.4 Cardiovascular Diseases
  • 8.5 Neurological Disorders
  • 8.6 Oncology
  • 8.7 Hormonal Disorders
  • 8.8 Other Chronic Diseases

9 Global Connected Drug Delivery Devices Market, By Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Retail Pharmacies
  • 9.3 Online Pharmacies
  • 9.4 Direct Sales

10 Global Connected Drug Delivery Devices Market, By End User

  • 10.1 Hospitals
  • 10.2 Clinics & Specialty Centers
  • 10.3 Home Care Settings
  • 10.4 Ambulatory Care Centers
  • 10.5 Pharmaceutical & Biotech Companies
  • 10.6 Patients & Caregivers

11 Global Connected Drug Delivery Devices Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Medtronic plc
  • 14.2 Becton, Dickinson and Company
  • 14.3 Ypsomed AG
  • 14.4 West Pharmaceutical Services, Inc.
  • 14.5 Phillips-Medisize Corporation
  • 14.6 Insulet Corporation
  • 14.7 Tandem Diabetes Care, Inc.
  • 14.8 Novo Nordisk A/S
  • 14.9 Teva Pharmaceutical Industries Ltd.
  • 14.10 AptarGroup, Inc.
  • 14.11 BIOCORP
  • 14.12 Adherium Limited
  • 14.13 Propeller Health
  • 14.14 Gerresheimer AG
  • 14.15 ResMed Inc.

List of Tables

  • Table 1 Global Connected Drug Delivery Devices Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Connected Drug Delivery Devices Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Connected Drug Delivery Devices Market Outlook, By Connected Sensors (2023-2034) ($MN)
  • Table 4 Global Connected Drug Delivery Devices Market Outlook, By Connected Inhaler Sensors (2023-2034) ($MN)
  • Table 5 Global Connected Drug Delivery Devices Market Outlook, By Connectable Injection Sensors (2023-2034) ($MN)
  • Table 6 Global Connected Drug Delivery Devices Market Outlook, By Add-on Smart Caps & Modules (2023-2034) ($MN)
  • Table 7 Global Connected Drug Delivery Devices Market Outlook, By Integrated Connected Devices (2023-2034) ($MN)
  • Table 8 Global Connected Drug Delivery Devices Market Outlook, By Connected Inhalers (2023-2034) ($MN)
  • Table 9 Global Connected Drug Delivery Devices Market Outlook, By Connected Injectable Devices (2023-2034) ($MN)
  • Table 10 Global Connected Drug Delivery Devices Market Outlook, By Smart Packaging & Monitoring Devices (2023-2034) ($MN)
  • Table 11 Global Connected Drug Delivery Devices Market Outlook, By Smart Pill Bottles (2023-2034) ($MN)
  • Table 12 Global Connected Drug Delivery Devices Market Outlook, By Smart Blister Packs (2023-2034) ($MN)
  • Table 13 Global Connected Drug Delivery Devices Market Outlook, By Technology (2023-2034) ($MN)
  • Table 14 Global Connected Drug Delivery Devices Market Outlook, By Bluetooth (2023-2034) ($MN)
  • Table 15 Global Connected Drug Delivery Devices Market Outlook, By Near Field Communication (NFC) (2023-2034) ($MN)
  • Table 16 Global Connected Drug Delivery Devices Market Outlook, By Wi-Fi (2023-2034) ($MN)
  • Table 17 Global Connected Drug Delivery Devices Market Outlook, By Cellular / LPWAN Connectivity (2023-2034) ($MN)
  • Table 18 Global Connected Drug Delivery Devices Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
  • Table 19 Global Connected Drug Delivery Devices Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 20 Global Connected Drug Delivery Devices Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 21 Global Connected Drug Delivery Devices Market Outlook, By Injectable / Parenteral (2023-2034) ($MN)
  • Table 22 Global Connected Drug Delivery Devices Market Outlook, By Inhalational (2023-2034) ($MN)
  • Table 23 Global Connected Drug Delivery Devices Market Outlook, By Oral Drug Delivery (2023-2034) ($MN)
  • Table 24 Global Connected Drug Delivery Devices Market Outlook, By Transdermal Delivery (2023-2034) ($MN)
  • Table 25 Global Connected Drug Delivery Devices Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 26 Global Connected Drug Delivery Devices Market Outlook, By Diabetes Management (2023-2034) ($MN)
  • Table 27 Global Connected Drug Delivery Devices Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 28 Global Connected Drug Delivery Devices Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
  • Table 29 Global Connected Drug Delivery Devices Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 30 Global Connected Drug Delivery Devices Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 31 Global Connected Drug Delivery Devices Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 32 Global Connected Drug Delivery Devices Market Outlook, By Hormonal Disorders (2023-2034) ($MN)
  • Table 33 Global Connected Drug Delivery Devices Market Outlook, By Other Chronic Diseases (2023-2034) ($MN)
  • Table 34 Global Connected Drug Delivery Devices Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 35 Global Connected Drug Delivery Devices Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 36 Global Connected Drug Delivery Devices Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 37 Global Connected Drug Delivery Devices Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 38 Global Connected Drug Delivery Devices Market Outlook, By Direct Sales (2023-2034) ($MN)
  • Table 39 Global Connected Drug Delivery Devices Market Outlook, By End User (2023-2034) ($MN)
  • Table 40 Global Connected Drug Delivery Devices Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 41 Global Connected Drug Delivery Devices Market Outlook, By Clinics & Specialty Centers (2023-2034) ($MN)
  • Table 42 Global Connected Drug Delivery Devices Market Outlook, By Home Care Settings (2023-2034) ($MN)
  • Table 43 Global Connected Drug Delivery Devices Market Outlook, By Ambulatory Care Centers (2023-2034) ($MN)
  • Table 44 Global Connected Drug Delivery Devices Market Outlook, By Pharmaceutical & Biotech Companies (2023-2034) ($MN)
  • Table 45 Global Connected Drug Delivery Devices Market Outlook, By Patients & Caregivers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.